NCT03198351View on ClinicalTrials.gov

An Observational Study on Teriflunomide-exposed Pregnancies

CompletedOBSERVATIONAL
Enrollment

220

Participants

Timeline

Start Date

April 25, 2013

Primary Completion Date

June 13, 2023

Study Completion Date

June 13, 2023

Conditions
Multiple Sclerosis
Interventions
DRUG

Teriflunomide (HMR1726)

"Pharmaceutical form: tablet~Route of administration: oral"

Trial Locations (2)

92093

University of California at San Diego-Site Number:001, San Diego

Unknown

Investigational Site Number :002, Canada

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT03198351 - An Observational Study on Teriflunomide-exposed Pregnancies | Biotech Hunter | Biotech Hunter